SCN3B Gene Brugada Syndrome Type 7 Genetic Test in UAE | 2800 AED | DHA Licensed

Name: SCN3B Gene Brugada Syndrome Type 7 Genetic Test
Brand: DNA Labs UAE
SKU: DX-LAB-4402
Price: 2800 AED
Availability: InStock

Executive Summary & Core Metrics

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via NGS technology processed in an ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited laboratory. Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM). Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with genetic counselling support. Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

DHA Facility License: 1143 | Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE

Test Overview & Methodology

The SCN3B Gene Brugada Syndrome Type 7 Genetic Test is a high-precision Next-Generation Sequencing assay that screens the SCN3B gene for pathogenic variants linked to Brugada Syndrome Type 7, a heritable cardiac channelopathy associated with elevated risk of ventricular arrhythmia and sudden cardiac death. This test is indicated for individuals with a clinical suspicion of Brugada Syndrome, a confirmed family history, or equivocal ECG findings requiring molecular confirmation for definitive diagnosis and risk stratification.

Feature	OUR TEST SCN3B NGS (UAE)	Closest Alternative
Methodology	NGS (Next-Generation Sequencing) — Full Gene Coverage	Standard Sanger Sequencing / Limited Panel
Diagnostic Sensitivity	99.9% — ISO 9001:2015 Validated	~95% — Variable QC Standards
Turnaround Time	21–28 Days (Expedited Available)	4–8 Weeks
Genetic Counselling	Included — Pre & Post-Test	Often Not Included
Regulatory Compliance	DHA-Licensed (Facility: 1143) \| UAE PDPL Compliant	Variable

Physician Insight & Safety Protocols

"As a Consultant Medical Genetics specialist registered with the DHA, I emphasize that a positive SCN3B variant must always be interpreted alongside a comprehensive 12-lead ECG, Holter monitoring, and detailed family history. A negative result does not exclude Brugada Syndrome, as other genes and non-genetic factors may contribute. Genetic testing is a powerful tool, but it is not a standalone verdict — clinical correlation is paramount."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory

⚠ Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Patients with suspected or confirmed Brugada Syndrome must avoid specific agents known to unmask or exacerbate Brugada ECG patterns. A comprehensive avoidance list — including certain antiarrhythmics (Class IC), psychotropic agents, and anesthetics — will be provided in your post-test clinical report. Always inform every treating physician of your Brugada diagnosis before any surgical procedure or new prescription.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: This test is not suitable as a standalone screening tool for asymptomatic individuals without a clinically confirmed Brugada ECG pattern (Type 1) or a documented family history of Brugada Syndrome or unexplained sudden cardiac death in a first-degree relative. Genetic testing of minors follows strict provisions requiring parental consent and clinical justification in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Emergency Red Flags — Seek Immediate Medical Attention: Unexplained syncope (fainting), nocturnal agonal respiration, documented polymorphic ventricular tachycardia, or seizure-like episodes during sleep. These symptoms in the context of a known or suspected Brugada diagnosis constitute a medical emergency.
Data Privacy Assurance: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genomic information is never shared with third parties without explicit, documented consent.

Patient FAQ & Clinical Guidance

1. What is the SCN3B Gene Brugada Syndrome Type 7 Genetic Test, and who should consider it?

The SCN3B Genetic Test is a high-resolution molecular diagnostic assay that sequences the entire coding region of the SCN3B gene to identify pathogenic variants responsible for Brugada Syndrome Type 7, a hereditary cardiac channelopathy that predisposes individuals to life-threatening ventricular arrhythmias and sudden cardiac death — even in the absence of structural heart disease. This test is recommended for individuals with a clinical suspicion of Brugada Syndrome, a confirmed family history of sudden cardiac death, or equivocal ECG findings requiring molecular confirmation for definitive diagnosis and risk stratification.

2. How is the sample collected, and what is the turnaround time for results?

Sample collection is performed via a minimally invasive blood draw (whole blood in EDTA tube, extracted DNA, or a single drop of blood on an FTA card) by a DHA-licensed phlebotomist during a scheduled home visit between 8 AM and 11 PM, with temperature-controlled cold-chain transport to our ISO-certified laboratory. Results are delivered within 21 to 28 days with an optional expedited processing pathway available upon request.

3. Is the SCN3B Brugada Syndrome genetic test covered by health insurance in the UAE?

Many UAE-based health insurance providers cover genetic testing for Brugada Syndrome when supported by a valid referral from a DHA-licensed cardiologist and documented clinical necessity. Our dedicated billing team verifies your insurance eligibility via direct coordination and provides confirmation through WhatsApp at +971 54 548 8731 before any out-of-pocket expense is incurred.

4. What pre-test information is required before undergoing this genetic test?

A comprehensive clinical history of the patient is required prior to testing. A pre-test genetic counselling session is mandatory to construct a detailed pedigree chart documenting all family members affected by or suspected of carrying SCN3B gene variants linked to Brugada Syndrome Type 7. Patients must disclose all current medications, particularly antiarrhythmics and psychotropic agents, during the pre-test consultation. Acceptable sample types include whole blood (EDTA tube), extracted DNA, or one drop of blood on an FTA card.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance: This service operates under DHA Facility License No. 1143 issued by the Dubai Health Authority. All procedures adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.

Accreditation: ISO 9001:2015 Certified — Certificate No. INT/EGQ/2509DA/3139.

Medical Disclaimer: This is a diagnostic aid and must be interpreted by a qualified, DHA-licensed clinical geneticist or cardiologist. It does not replace comprehensive cardiac evaluation, including 12-lead ECG, electrophysiology studies, or clinical risk stratification.

Contact: WhatsApp Support: +971 54 548 8731 | Home Collection Hours: 8 AM – 11 PM Daily

Clinical & Logistical Metadata

Test Name	SCN3B Gene Brugada Syndrome Type 7 Genetic Test (NGS)
Price (AED)	2,800 AED
Turnaround Time	21–28 Days (Expedited Available)
Sample Type / Matrix	Whole Blood (EDTA tube), Extracted DNA, or FTA Card Blood Spot
Methodology Used	Next-Generation Sequencing (NGS) — Full Gene Coverage
ICD-10-CM Code	I49.8
LOINC Code	88508-6
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE